トゥレット症候群治療薬の世界市場:抗精神病薬、非抗精神病薬

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antipsychotics – Market size and forecast 2018-2023
• Non-antipsychotics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Development of novel therapeutics
• Increasing strategic alliances
• Growing number of research studies to understand genetic root cause of
• Tourette’s syndrome
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• H. Lundbeck AS
• Johnson & Johnson Services Inc.
• Mylan NV
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antipsychotics – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antipsychotics – Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-antipsychotics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-antipsychotics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca Plc – Vendor overview
Exhibit 49: AstraZeneca Plc – Business segments
Exhibit 50: AstraZeneca Plc – Organizational developments
Exhibit 51: AstraZeneca Plc – Geographic focus
Exhibit 52: AstraZeneca Plc – Key offerings
Exhibit 53: AstraZeneca Plc – Key customers
Exhibit 54: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 55: Boehringer Ingelheim International GmbH – Business segments
Exhibit 56: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 57: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 58: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 59: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 60: Boehringer Ingelheim International GmbH – Key customers
Exhibit 61: Eli Lilly and Co. – Vendor overview
Exhibit 62: Eli Lilly and Co. – Business segments
Exhibit 63: Eli Lilly and Co. – Organizational developments
Exhibit 64: Eli Lilly and Co. – Geographic focus
Exhibit 65: Eli Lilly and Co. – Segment focus
Exhibit 66: Eli Lilly and Co. – Key offerings
Exhibit 67: Eli Lilly and Co. – Key customers
Exhibit 68: H. Lundbeck AS – Vendor overview
Exhibit 69: H. Lundbeck AS – Business segments
Exhibit 70: H. Lundbeck AS – Organizational developments
Exhibit 71: H. Lundbeck AS – Geographic focus
Exhibit 72: H. Lundbeck AS – Key offerings
Exhibit 73: H. Lundbeck AS – Key customers
Exhibit 74: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 75: Johnson & Johnson Services Inc. – Business segments
Exhibit 76: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 77: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 78: Johnson & Johnson Services Inc. – Segment focus
Exhibit 79: Johnson & Johnson Services Inc. – Key offerings
Exhibit 80: Johnson & Johnson Services Inc. – Key customers
Exhibit 81: Mylan NV – Vendor overview
Exhibit 82: Mylan NV – Product segments
Exhibit 83: Mylan NV – Organizational developments
Exhibit 84: Mylan NV – Geographic focus
Exhibit 85: Mylan NV – Segment focus
Exhibit 86: Mylan NV – Key offerings
Exhibit 87: Mylan NV – Key customers
Exhibit 88: Otsuka Holdings Co. Ltd. – Vendor overview
Exhibit 89: Otsuka Holdings Co. Ltd. – Business segments
Exhibit 90: Otsuka Holdings Co. Ltd. – Organizational developments
Exhibit 91: Otsuka Holdings Co. Ltd. – Geographic focus
Exhibit 92: Otsuka Holdings Co. Ltd. – Segment focus
Exhibit 93: Otsuka Holdings Co. Ltd. – Key offerings
Exhibit 94: Otsuka Holdings Co. Ltd. – Key customers
Exhibit 95: Pfizer Inc. – Vendor overview
Exhibit 96: Pfizer Inc. – Business segments
Exhibit 97: Pfizer Inc. – Organizational developments
Exhibit 98: Pfizer Inc. – Geographic focus
Exhibit 99: Pfizer Inc. – Segment focus
Exhibit 100: Pfizer Inc. – Key offerings
Exhibit 101: Pfizer Inc. – Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様